341 related articles for article (PubMed ID: 36856733)
1. Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment.
Burman P; Casar-Borota O; Perez-Rivas LG; Dekkers OM
J Clin Endocrinol Metab; 2023 Jun; 108(7):1585-1601. PubMed ID: 36856733
[TBL] [Abstract][Full Text] [Related]
2. Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients.
Burman P; Trouillas J; Losa M; McCormack A; Petersenn S; Popovic V; Theodoropoulou M; Raverot G; Dekkers OM;
Eur J Endocrinol; 2022 Oct; 187(4):593-605. PubMed ID: 36018781
[TBL] [Abstract][Full Text] [Related]
3. Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study.
Ilie MD; Villa C; Cuny T; Cortet C; Assie G; Baussart B; Cancel M; Chanson P; Decoudier B; Deluche E; Di Stefano AL; Drui D; Gaillard S; Goichot B; Huillard O; Joncour A; Larrieu-Ciron D; Libe R; Nars G; Vasiljevic A; Raverot G
Eur J Endocrinol; 2022 Nov; 187(5):685-696. PubMed ID: 36111659
[TBL] [Abstract][Full Text] [Related]
4. [Aggressive pituitary adenoma and pituitary carcinoma].
Tóth M
Orv Hetil; 2023 Jul; 164(30):1167-1175. PubMed ID: 37516994
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide in aggressive pituitary tumours and pituitary carcinomas.
McCormack A
Best Pract Res Clin Endocrinol Metab; 2022 Dec; 36(6):101713. PubMed ID: 36274026
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in pituitary carcinomas and aggressive pituitary tumors.
Raverot G; Ilie MD
Best Pract Res Clin Endocrinol Metab; 2022 Dec; 36(6):101712. PubMed ID: 36274025
[TBL] [Abstract][Full Text] [Related]
7. Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors.
Nakano-Tateno T; Lau KJ; Wang J; McMahon C; Kawakami Y; Tateno T; Araki T
Front Endocrinol (Lausanne); 2021; 12():624686. PubMed ID: 33841328
[TBL] [Abstract][Full Text] [Related]
8. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
9. Aggressive pituitary tumours and pituitary carcinomas.
Raverot G; Ilie MD; Lasolle H; Amodru V; Trouillas J; Castinetti F; Brue T
Nat Rev Endocrinol; 2021 Nov; 17(11):671-684. PubMed ID: 34493834
[TBL] [Abstract][Full Text] [Related]
10. Aggressive corticotroph tumors and carcinomas.
Lasolle H; Vasiljevic A; Jouanneau E; Ilie MD; Raverot G
J Neuroendocrinol; 2022 Aug; 34(8):e13169. PubMed ID: 35979732
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas.
Minniti G; Paolini S; Rea MLJ; Isidori A; Scaringi C; Russo I; Osti MF; Cavallo L; Esposito V
J Neurooncol; 2020 Aug; 149(1):123-130. PubMed ID: 32632895
[TBL] [Abstract][Full Text] [Related]
12. Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations.
Casar-Borota O; Boldt HB; Engström BE; Andersen MS; Baussart B; Bengtsson D; Berinder K; Ekman B; Feldt-Rasmussen U; Höybye C; Jørgensen JOL; Kolnes AJ; Korbonits M; Rasmussen ÅK; Lindsay JR; Loughrey PB; Maiter D; Manojlovic-Gacic E; Pahnke J; Poliani PL; Popovic V; Ragnarsson O; Schalin-Jäntti C; Scheie D; Tóth M; Villa C; Wirenfeldt M; Kunicki J; Burman P
J Clin Endocrinol Metab; 2021 Mar; 106(4):1183-1194. PubMed ID: 33106857
[TBL] [Abstract][Full Text] [Related]
13. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
Lizzul L; Lombardi G; Barbot M; Ceccato F; Gardiman MP; Regazzo D; Bellu L; Mazza E; Losa M; Scaroni C
Pituitary; 2020 Aug; 23(4):359-366. PubMed ID: 32232709
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey.
Elbelt U; Schlaffer SM; Buchfelder M; Knappe UJ; Vila G; Micko A; Deutschbein T; Unger N; Lammert A; Topuzoglu-Müller T; Bojunga J; Droste M; Johanssen S; Kolenda H; Ritzel K; Buslei R; Strasburger CJ; Petersenn S; Honegger J
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31746334
[TBL] [Abstract][Full Text] [Related]
15. Medical Therapy of Aggressive Pituitary Tumors.
Petersenn S
Exp Clin Endocrinol Diabetes; 2021 Mar; 129(3):186-193. PubMed ID: 33690871
[TBL] [Abstract][Full Text] [Related]
16. Aggressive pituitary tumors and carcinomas: medical treatment beyond temozolomide.
DE Alcubierre D; Carretti AL; Ducray F; Jouanneau E; Raverot G; Ilie MD
Minerva Endocrinol (Torino); 2024 Jan; ():. PubMed ID: 38240681
[TBL] [Abstract][Full Text] [Related]
17. Pituitary carcinoma - case series and review of the literature.
Du Four S; Van Der Veken J; Duerinck J; Vermeulen E; Andreescu CE; Bruneau M; Neyns B; Velthoven V; Velkeniers B
Front Endocrinol (Lausanne); 2022; 13():968692. PubMed ID: 36157469
[TBL] [Abstract][Full Text] [Related]
18. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.
Raverot G; Burman P; McCormack A; Heaney A; Petersenn S; Popovic V; Trouillas J; Dekkers OM;
Eur J Endocrinol; 2018 Jan; 178(1):G1-G24. PubMed ID: 29046323
[TBL] [Abstract][Full Text] [Related]
19. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.
McCormack A; Dekkers OM; Petersenn S; Popovic V; Trouillas J; Raverot G; Burman P;
Eur J Endocrinol; 2018 Mar; 178(3):265-276. PubMed ID: 29330228
[TBL] [Abstract][Full Text] [Related]
20. Treatment Options for Gonadotroph Tumors: Current State and Perspectives.
Ilie MD; Raverot G
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32735647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]